Filter posts

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

As biopharmaceutical manufacturers consider the new reality of accountable care organizations (ACOs) and the impact …

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead …

The Rise of Specialty Pharmaceuticals

Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, …

The Ethics of the Market Access Debate

At the core of the market access conversation lies the question of value. How much …

Alzheimer’s Disease “Robs You of Everything”

George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood …

Biomedical R&D in the 21st Century

Reflecting back upon my career,  I recognize the importance academic-industry research partnerships played in shaping …

#BIO 2013: Open Innovation and Biopharmaceutical R&D

In these changing times, the concept of Open Innovation is one that we at AstraZeneca …

Q & A with Eli Lilly’s Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase …

New Challenges in the Fast Changing Landscape of Bioinformatics

The world of DNA sequencing and bioinformatics has evolved at a staggering pace. In 2009, …

Worldwide Orphan Drug Market to Grow to $127 Billion by 2018

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international …